Published: June 2026
A major new clinical trial just answered one of oncology's most pressing questions — and the answer is more complicated than anyone hoped.
Table of Contents
- What
You Need to Know First
- What
Is ctDNA, and Why Does It Matter for Colorectal Cancer?
- The
ALTAIR Trial: What Happened and What Was Studied
- What
the Trial Found
- What
Is ctDNA Clearance, and Why Does It Predict Survival?
- The
Trade-Offs: What About Side Effects?
- What
This Means for Colorectal Cancer Patients Right Now
- The
Bigger Picture: Where Is Colorectal Cancer Treatment Heading?
- The
Bottom Line
- Key
Takeaways
1. What You Need to Know First
Colorectal
cancer is one of the most common and deadly cancers in the world. In the
United States alone, the American
Cancer Society estimates over 154,000 new cases are diagnosed every year,
making it the third most common cancer in both men and women. The good news?
When caught early and surgically removed, it can often be cured. The bad news?
Even after a successful operation, roughly 1 in 5 patients will see
their cancer return — and for those with metastatic disease that was surgically
removed, recurrence rates can be as high as 40–60%.
For
years, oncologists have been searching for a smarter way to find out who is at
risk of recurrence before the disease becomes visible on CT scans or
MRIs. That search has led to one of the most exciting tools in modern cancer
medicine: circulating tumor DNA, or ctDNA — a type of liquid
biopsy that detects cancer signals directly from a blood sample.
And
now, a landmark phase 3 clinical trial called ALTAIR — published in Nature
Medicine in June 2026 — has put ctDNA-guided treatment to the biggest
test yet. The results are nuanced, honest, and critically important for every
patient, caregiver, and clinician navigating colorectal cancer treatment today.
2. What Is ctDNA, and Why Does It Matter for Colorectal Cancer?
When
cancer cells die or divide, they shed tiny fragments of their DNA into the
bloodstream. This is called circulating tumor DNA, or ctDNA. Think of it
as a molecular fingerprint your blood carries after cancer surgery — even when
all visible signs of disease appear to be gone.
The National
Cancer Institute describes ctDNA testing as a minimally invasive way to
detect cancer-related changes in the blood that may help doctors better
understand a patient's cancer and guide treatment decisions. It's part of a
broader category of tests known as liquid biopsies.
In
colorectal cancer specifically, ctDNA has become one of the most powerful
prognostic tools available. Research published in Nature Medicine
has consistently shown that patients who test ctDNA-positive after
surgery have a dramatically higher chance of their cancer returning — even when
their CT scans look completely clear. Patients who test ctDNA-negative,
on the other hand, have a much lower risk of relapse.
This
has led to an obvious but enormously important question: If we can detect
leftover cancer at the molecular level, can we treat it early and improve
survival?
That's
exactly what the ALTAIR trial was designed to find out.
3. The ALTAIR Trial: What Happened and What Was Studied
The Setup
ALTAIR
was a randomized, double-blind, phase 3 clinical trial — the gold standard in
medical research. It was part of the larger CIRCULATE-Japan platform, one of the
most ambitious colorectal cancer surveillance programs ever conducted,
enrolling over 5,500 patients across 152 hospitals in Japan and Taiwan.
Researchers
followed patients who had undergone surgery for colorectal cancer (stages 0
through IV) and had completed their standard-of-care treatment. Using a highly
sensitive, personalized ctDNA test called Signatera
(developed by Natera), they monitored patients' blood regularly after surgery.
Signatera is a tumor-informed assay — meaning it's custom-built from each
patient's own tumor DNA to track up to 16 unique cancer mutations in their
bloodstream.
When
a patient turned ctDNA-positive — meaning cancer DNA was detected in the blood
even though scans showed no visible disease — they became eligible for the
ALTAIR trial. This condition is known as molecular residual disease (MRD):
the cancer has left microscopic traces behind, invisible to conventional
imaging.
The Question
Between
July 2020 and June 2023, 243 ctDNA-positive patients with no visible cancer on
imaging were enrolled and randomly split into two groups:
- 122
patients received trifluridine/tipiracil
(FTD/TPI), a chemotherapy drug already FDA-approved
for metastatic colorectal cancer
- 121
patients received a placebo
Both
groups were followed closely to see how long they remained free of detectable
cancer recurrence — a measure called disease-free survival (DFS).
4. What the Trial Found
The Main Result
The
median disease-free survival was 9.30 months in the FTD/TPI group vs. 5.55
months in the placebo group. That's a nearly 4-month difference — and at 6
months, 70.5% of patients on FTD/TPI were still disease-free, compared to only
45.5% of those on placebo.
Sounds
promising, right?
Here's
the catch: statistically, the trial did not meet its primary endpoint.
The result (hazard ratio of 0.79, p = 0.107) fell just short of the
significance threshold needed to confidently declare FTD/TPI an effective
treatment in this setting. In clinical trial terms, that means the data isn't
strong enough to say with certainty that the drug works — the difference could,
in theory, be due to chance.
The Silver Lining
Not
everything was inconclusive. An independent review of all imaging data — done
by radiologists who didn't know which patients had received which treatment —
found a statistically significant benefit for FTD/TPI, with a hazard
ratio of 0.75 and a p-value of 0.04. That's just over the significance
threshold.
More
notably, patients with stage IV colorectal cancer (where disease had
spread but was surgically removed) seemed to benefit most. In that group, the
hazard ratio was 0.53 — meaning patients on FTD/TPI had about half the risk of
recurrence at any given time compared to placebo. The median DFS in stage IV patients
was 9.7 months vs. 3.9 months on placebo.
These
are exploratory findings, not definitive conclusions — but they suggest that
certain patients might benefit meaningfully from this approach.
5. What Is ctDNA Clearance, and Why Does It Predict Survival?
One
of the most fascinating findings from ALTAIR had nothing to do with whether the
drug worked — it was about what ctDNA does over time.
The
researchers tracked ctDNA levels throughout the study and categorized patients
into three groups:
- Sustained
clearance — blood tests turned negative and stayed
negative
- Transient
clearance — blood tests turned negative but later
became positive again
- No
clearance — ctDNA remained detectable throughout
The
survival differences between these groups were striking. Patients who achieved sustained
ctDNA clearance had a median disease-free survival that wasn't even reached
during the study — meaning most were still disease-free at the time of
analysis. Those with transient clearance had a median DFS of about 11.7
months. Those with no clearance had a median DFS of just 4.4 months.
This
aligns with earlier research from the CIRCULATE-Japan
GALAXY study, which established ctDNA clearance as a powerful predictor of
long-term outcomes in resectable colorectal cancer.
Put
simply: what happens to your ctDNA level after treatment tells us a great
deal about what's going to happen to you. Whether or not FTD/TPI was
responsible for the clearance, the act of clearing ctDNA — however it happened
— was strongly linked to staying cancer-free longer.
6. The Trade-Offs: What About Side Effects?
This
is where patients and clinicians need to think carefully.
FTD/TPI
(brand name: Lonsurf) is not a gentle drug. According to the prescribing
information and the ALTAIR trial data:
- 98.4% of
patients in the FTD/TPI group had at least one adverse event (vs. 57% on
placebo)
- 73% of
FTD/TPI patients experienced grade 3 or higher hematologic side effects —
meaning serious drops in white blood cells, neutrophils, or other blood
counts (vs. just 3.3% on placebo)
- Nearly 38%
of FTD/TPI patients required dose reductions
Quality
of life scores during treatment, measured using the validated EORTC
QLQ-C30 questionnaire, were significantly lower in the FTD/TPI group,
particularly in the first 8 weeks. The good news: once treatment ended, quality
of life recovered and the two groups looked similar by week 24.
No
treatment-related deaths occurred, and no new safety signals were identified.
Still
— these are serious side effects in a group of patients who have no visible
cancer on their scans. The benefit needs to clearly outweigh the risk, and the
ALTAIR trial suggests we aren't quite there yet for most patients, at least
with FTD/TPI at these doses.
7. What This Means for Colorectal Cancer Patients Right Now
If
you or a loved one has been treated for colorectal cancer, here's what this
research means in practical terms:
1. Blood-based ctDNA testing is increasingly standard — and
meaningful. If you've had colorectal cancer surgery, ask your oncologist about
ctDNA monitoring. The NCCN
Guidelines for Colorectal Cancer are increasingly incorporating
biomarker-based surveillance into follow-up recommendations. A positive result
doesn't mean the end of the road — it means your team has an earlier warning
signal to act on.
2. A positive ctDNA result after treatment is serious, but not a
death sentence. About 9% of patients in this trial who received only placebo still
achieved ctDNA clearance on their own. This suggests that some early molecular
signals may reflect low-level biological fluctuation rather than confirmed
recurrence. Your oncologist needs to assess your full clinical picture.
3. Treatment options for ctDNA-positive patients are still being
developed. FTD/TPI showed hints of benefit — particularly in patients with
stage IV disease — but didn't cross the bar for a definitive recommendation.
You can track ongoing clinical trials in this space at ClinicalTrials.gov,
where several new studies are enrolling.
4. Stage IV patients may stand to gain the most from this approach. If you were
treated for oligometastatic colorectal cancer (where cancer had spread to one
or a few sites and was surgically removed), and your ctDNA comes back positive
during surveillance, discuss the ALTAIR findings with your care team. The
subgroup data is promising enough to warrant a serious conversation.
8. The Bigger Picture: Where Is Colorectal Cancer Treatment
Heading?
The
ALTAIR trial is one piece of a much larger puzzle. Here's the broader
landscape:
ctDNA-Guided Treatment Is Becoming Real
The DYNAMIC-II trial,
published in the New England Journal of Medicine, showed that
ctDNA-guided decisions for stage II colon cancer can reduce chemotherapy use
without worsening outcomes — a major quality-of-life win. The DYNAMIC-III trial,
however, showed that escalating treatment based on ctDNA positivity didn't
improve outcomes in stage III disease.
What
these trials together suggest is that which treatment you use in response to
a positive ctDNA signal matters enormously. Not all interventions are
created equal.
The "Treat on Molecular Recurrence" Concept
ALTAIR
was the first phase 3 trial to test what researchers call "treat on
molecular recurrence" (TOMR) — starting treatment when ctDNA turns
positive but before any visible disease appears. This is a fundamentally
different paradigm from traditional oncology, and ALTAIR proved it's feasible
even if FTD/TPI wasn't the right drug at the right dose.
Future
trials will test different agents — potentially combining FTD/TPI with
anti-angiogenic drugs like bevacizumab,
which has already shown improved survival in advanced colorectal cancer — or
using immunotherapy
in patients with mismatch-repair deficient tumors, a subtype that has responded
dramatically to PD-1
blockade.
Personalized Treatment Is the Future
One
of the most important insights from ALTAIR is that not all ctDNA-positive
patients are the same. Those with stage IV disease, higher baseline ctDNA
levels, or certain tumor characteristics may respond very differently to
treatment than stage I–III patients. As researchers learn to refine patient
selection, future trials may identify subgroups who benefit dramatically.
Organizations
like the Colorectal Cancer Alliance
and the American
Society of Clinical Oncology (ASCO) continue to publish updated guidance as
these results emerge. Staying connected to these resources can help patients
and families make informed decisions.
9. The Bottom Line
The
ALTAIR trial didn't deliver the clean, clear win that researchers and patients
were hoping for. FTD/TPI did not significantly extend disease-free survival in
the overall ctDNA-positive population.
But
it taught us something just as important: treating colorectal cancer based
on molecular signals is scientifically sound, logistically feasible, and
potentially beneficial in the right patients. The framework is real. The
biomarker works. We just need the right therapeutic strategy to match it.
For
the roughly 1 in 5 colorectal cancer patients who will face recurrence — and
for the thousands who may be ctDNA-positive right now without knowing it —
that's not a failure. That's progress.
10. Key Takeaways
- Colorectal
cancer recurs in 20–60% of patients after
surgery, even when it appears to be fully removed
- ctDNA
(circulating tumor DNA) is a blood test that can detect molecular
traces of cancer before they appear on scans
- The ALTAIR
phase 3 trial tested whether early treatment with FTD/TPI could
prevent recurrence in ctDNA-positive colorectal cancer patients
- FTD/TPI
showed a numerical benefit (9.3 vs. 5.5 months disease-free survival) but
did not reach statistical significance in the overall trial population
- Stage IV
colorectal cancer patients showed the strongest potential benefit
from early ctDNA-guided treatment
- Sustained
ctDNA clearance — regardless of treatment — was
powerfully linked to better long-term outcomes
- This
research paves the way for future trials with better-targeted treatments
and smarter patient selection
This article is intended for informational purposes only and does
not constitute medical advice. If you have been diagnosed with colorectal
cancer or have concerns about your health, please speak with a qualified
healthcare professional. For support and resources, visit the Colorectal Cancer Alliance or call the National
Cancer Information Center at 1-800-227-2345.
Comments
Post a Comment